These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK’s Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Mydecine Innovations Group Inc.
Psyched: Musk’s Empathy Tweets, Psychedelics In Congress, Oregon’s Opt-Outs, MAPS’ MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Mydecine’s Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine months ended September 30, 2022.
World Class Leaders In Psychedelics Form Benzinga’s Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape.
Mydecine Innovations Group Announces Private Placement Of 326,666 Shares At $0.75/Share
https://www.globenewswire.com/news-release/2022/08/19/2501703/0/en/Mydecine-Innovations-Group-Announces-Private-Placement-Interim-Changes-to-Management-and-Board-of-Directors.html
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here’s What Could Change
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.
Government-Funded Smoking Cessation Trial Uses Mydecine’s New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product.
Mydecine Announces 1-for-50 Reverse Stock Split
The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding shares on a base of 1-for-50.
According to Mydecine, the consolidation is expected to reduce the number of common shares from 268,515,954 to 5,370,319.